[HTML][HTML] Targeted sequencing of plasma-derived vs. urinary cfDNA from patients with triple-negative breast cancer
H Herzog, S Dogan, B Aktas, I Nel - Cancers, 2022 - mdpi.com
Simple Summary Circulating cell-free DNA displays vast potential to capture the entire
genetic landscape of a tumor and to characterize intratumoral heterogeneity, providing a …
genetic landscape of a tumor and to characterize intratumoral heterogeneity, providing a …
Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer
H Herzog, S Dogan, B Aktas, I Nel - 2022 - ul.qucosa.de
Abstract (EN) In breast cancer, the genetic profiling of circulating cell-free DNA (cfDNA) from
blood plasma was shown to have good potential for clinical use. In contrast, only a few …
blood plasma was shown to have good potential for clinical use. In contrast, only a few …
Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer
H Herzog, S Dogan, B Aktas, I Nel - Cancers, 2022 - search.proquest.com
In breast cancer, the genetic profiling of circulating cell-free DNA (cfDNA) from blood plasma
was shown to have good potential for clinical use. In contrast, only a few studies were …
was shown to have good potential for clinical use. In contrast, only a few studies were …
Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer.
H Herzog, S Dogan, B Aktas, I Nel - Cancers, 2022 - europepmc.org
In breast cancer, the genetic profiling of circulating cell-free DNA (cfDNA) from blood plasma
was shown to have good potential for clinical use. In contrast, only a few studies were …
was shown to have good potential for clinical use. In contrast, only a few studies were …
Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer.
H Herzog, S Dogan, B Aktas, I Nel - Cancers, 2022 - search.ebscohost.com
Abstract Simple Summary: Circulating cell-free DNA displays vast potential to capture the
entire genetic landscape of a tumor and to characterize intratumoral heterogeneity …
entire genetic landscape of a tumor and to characterize intratumoral heterogeneity …
Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer
H Herzog, S Dogan, B Aktas, I Nel - Cancers, 2022 - pubmed.ncbi.nlm.nih.gov
In breast cancer, the genetic profiling of circulating cell-free DNA (cfDNA) from blood plasma
was shown to have good potential for clinical use. In contrast, only a few studies were …
was shown to have good potential for clinical use. In contrast, only a few studies were …
[HTML][HTML] Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer
H Herzog, S Dogan, B Aktas, I Nel - Cancers, 2022 - ncbi.nlm.nih.gov
In breast cancer, the genetic profiling of circulating cell-free DNA (cfDNA) from blood plasma
was shown to have good potential for clinical use. In contrast, only a few studies were …
was shown to have good potential for clinical use. In contrast, only a few studies were …
Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer.
H Herzog, S Dogan, B Aktas, I Nel - Cancers, 2022 - europepmc.org
In breast cancer, the genetic profiling of circulating cell-free DNA (cfDNA) from blood plasma
was shown to have good potential for clinical use. In contrast, only a few studies were …
was shown to have good potential for clinical use. In contrast, only a few studies were …